Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;9(2):CNS59.
doi: 10.2217/cns-2020-0008. Epub 2020 Jun 30.

Disparities in patient enrollment on glioblastoma clinical trials

Yang Liu  1 , Andrea Wasilewski  1 , Nimish A Mohile  1
Affiliations

Disparities in patient enrollment on glioblastoma clinical trials

Yang Liu et al. CNS Oncol. 2020 Jun.

Abstract

Aim: To determine if enrollment on glioblastoma (GBM) interventional clinical trials (ICTs) in the USA is representative of the population. Materials & methods: We queried ClinicalTrials.gov for all ICTs in GBM from 1994 to 2019. Demographics were obtained from ClinicalTrials.gov or the trial publication and compared with population data from Central Brain Tumor Registry of the United States. Results: In total, 10617 GBM patients were enrolled in 118 adult ICTs: median age was 54.0 (10.05 years younger than Central Brain Tumor Registry of the United States). Age was most discrepant in recurrent tumors, nonrandomized trials and consortium studies. Median age improved from 52.0 to 59.5 over 25 years. Women represented 37.5% of subjects. Conclusion: GBM ICTs under-represent older patients but representation of women reflects the population. ICTs need to be designed to better represent the population.

Keywords: age and sex disparities; clinical trials; glioblastoma; trends.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Flowchart of clinical trials identification for the current study.
Study inclusion criteria was detailed in the ‘Method’.
Figure 2.
Figure 2.. Time changes of difference in median age.
**p < 0.01.
See this image and copyright information in PMC

References

    1. Stupp R, Mason WP, van den Bent MJ. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005). - PubMed
    1. Chinot OL, Wick W, Mason W. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370(8), 709–722 (2014). - PubMed
    1. Stupp R, Taillibert S, Kanner A. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23), 2306–2316 (2017). - PMC - PubMed
    1. Hurria A, Naylor M, Cohen HJ. Improving the quality of cancer care in an aging population: recommendations from an IOM report. JAMA 310(17), 1795–1796 (2013). - PubMed
    1. Freedman RA, Ruddy KJ. Who are the patients in our clinical trials for cancer? J. Clin. Oncol. 37(18), 1519–1523 (2019). - PubMed

MeSH terms